(0.63%) 5 078.50 points
(0.44%) 38 235 points
(0.79%) 17 577 points
(0.99%) $79.78
(1.35%) $1.958
(-0.14%) $2 307.70
(-0.82%) $26.53
(0.61%) $960.70
(0.18%) $0.935
(0.34%) $11.07
(0.12%) $0.799
(-1.42%) $91.94
Live Chart Being Loaded With Signals
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China...
Stats | |
---|---|
本日の出来高 | 512 300 |
平均出来高 | 1.39M |
時価総額 | 5.44B |
EPS | HKD0 ( 2023-08-21 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -5.29 |
ATR14 | HKD0.0160 (0.09%) |
ボリューム 相関
Ascentage Pharma Group 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ascentage Pharma Group 相関 - 通貨/商品
Ascentage Pharma Group 財務諸表
Annual | 2023 |
収益: | HKD221.98M |
総利益: | HKD191.44M (86.24 %) |
EPS: | HKD-3.37 |
FY | 2023 |
収益: | HKD221.98M |
総利益: | HKD191.44M (86.24 %) |
EPS: | HKD-3.37 |
FY | 2022 |
収益: | HKD209.71M |
総利益: | HKD187.71M (89.51 %) |
EPS: | HKD-3.35 |
FY | 2021 |
収益: | HKD27.91M |
総利益: | HKD24.58M (88.08 %) |
EPS: | HKD-3.07 |
Financial Reports:
No articles found.
Ascentage Pharma Group
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。